Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Interest Expenses (2022 - 2025)

Autolus Therapeutics (AUTL) has disclosed Interest Expenses for 4 consecutive years, with $10.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 1.55% year-over-year to $10.5 million, compared with a TTM value of -$17.0 million through Sep 2025, down 124.2%, and an annual FY2024 reading of $9.3 million, down 79.38% over the prior year.
  • Interest Expenses was $10.5 million for Q3 2025 at Autolus Therapeutics, up from -$6.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $30.1 million in Q4 2023 and bottomed at -$30.8 million in Q4 2024.
  • Average Interest Expenses over 4 years is $5.1 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Interest Expenses skyrocketed 772.01% in 2023, then plummeted 202.35% in 2024.
  • Year by year, Interest Expenses stood at $3.5 million in 2022, then surged by 772.01% to $30.1 million in 2023, then tumbled by 202.35% to -$30.8 million in 2024, then skyrocketed by 134.12% to $10.5 million in 2025.
  • Business Quant data shows Interest Expenses for AUTL at $10.5 million in Q3 2025, -$6.8 million in Q2 2025, and $10.1 million in Q1 2025.